Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation

• Autors principals: Andrea Mortara (Autor), Simone Mazzetti (Autor), Davide Margonato (Autor), Pietro Delfino (Autor), Chiara Bersano (Autor), Francesco Catagnano (Autor), Marinella Lauriola (Autor), Paolo Grosso (Autor), Gianluca Perseghin (Autor), Giovanbattista Ippoliti (Autor)
• Format: Llibre
• Publicat: Wiley, 2021-05-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Ruxolitinib is an anti‐inflammatory drug that inhibits the Janus kinase‐signal transducer (JAK‐STAT) pathway on the surface of immune cells. The potential targeting of this pathway using JAK inhibitors is a promising approach in patients affected by coronavirus disease 2019 (COVID‐19). Ruxo...